PT Kimia Farma Tbk (IDX:KAEF)
Indonesia · Delayed Price · Currency is IDR 555.00
+5.00 (0.91%)
Aug 5, 2025, 3:49 PM WIB
Revance Therapeutics Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 9,571,387 | 9,938,958 | 9,871,842 | 9,232,676 | 12,857,627 | 10,006,173 | Upgrade | |
Revenue Growth (YoY) | -5.27% | 0.68% | 6.92% | -28.19% | 28.50% | 6.44% | Upgrade |
Cost of Revenue | 7,017,062 | 7,306,468 | 7,386,245 | 5,717,521 | 8,811,444 | 6,676,370 | Upgrade |
Gross Profit | 2,554,325 | 2,632,490 | 2,485,598 | 3,515,154 | 4,046,183 | 3,329,803 | Upgrade |
Selling, General & Admin | 3,013,154 | 3,105,290 | 3,681,094 | 2,889,203 | 2,860,390 | 2,791,532 | Upgrade |
Research & Development | 31,620 | 31,620 | 107,234 | 46,365 | 41,348 | 15,527 | Upgrade |
Other Operating Expenses | -56,299 | -54,122 | 55,091 | -134,094 | -39,660 | -291,419 | Upgrade |
Operating Expenses | 3,311,740 | 3,406,054 | 4,197,867 | 3,009,321 | 3,090,225 | 2,665,806 | Upgrade |
Operating Income | -757,415 | -773,563 | -1,712,269 | 505,834 | 955,958 | 663,997 | Upgrade |
Interest Expense | -620,588 | -640,832 | -597,149 | -525,608 | -606,813 | -596,377 | Upgrade |
Interest & Investment Income | 10,283 | 10,283 | 33,183 | 12,166 | 22,735 | 25,524 | Upgrade |
Currency Exchange Gain (Loss) | -1,590 | -1,966 | -2,044 | -1,138 | 6,637 | -8,282 | Upgrade |
Other Non Operating Income (Expenses) | 214,217 | 214,020 | - | - | - | -27,699 | Upgrade |
EBT Excluding Unusual Items | -1,155,093 | -1,192,057 | -2,278,280 | -8,747 | 378,517 | 57,162 | Upgrade |
Impairment of Goodwill | -53,877 | -53,877 | -26,889 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | 15,153 | 15,153 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 804.32 | 804.32 | 2,022 | -13,603 | 2,112 | 443.07 | Upgrade |
Asset Writedown | 278.48 | 278.48 | 22,703 | 5,956 | 12,254 | 15,754 | Upgrade |
Pretax Income | -1,192,734 | -1,229,699 | -2,280,444 | -16,394 | 392,883 | 73,359 | Upgrade |
Income Tax Expense | 34.48 | -21,526 | -19,760 | 94,175 | 102,995 | 52,933 | Upgrade |
Earnings From Continuing Operations | -1,192,769 | -1,208,173 | -2,260,684 | -110,568 | 289,889 | 20,426 | Upgrade |
Earnings From Discontinued Operations | - | - | - | -15,456 | - | - | Upgrade |
Net Income to Company | -1,192,769 | -1,208,173 | -2,260,684 | -126,024 | 289,889 | 20,426 | Upgrade |
Minority Interest in Earnings | 351,053 | 365,900 | 296,528 | -64,448 | 12,385 | -2,787 | Upgrade |
Net Income | -841,716 | -842,272 | -1,964,157 | -190,473 | 302,274 | 17,639 | Upgrade |
Net Income to Common | -841,716 | -842,272 | -1,964,157 | -190,473 | 302,274 | 17,639 | Upgrade |
Net Income Growth | - | - | - | - | 1613.68% | - | Upgrade |
Shares Outstanding (Basic) | - | 5,567 | 5,562 | 5,561 | 5,554 | 5,554 | Upgrade |
Shares Outstanding (Diluted) | - | 5,567 | 5,562 | 5,561 | 5,554 | 5,554 | Upgrade |
Shares Change (YoY) | - | 0.08% | 0.01% | 0.13% | - | - | Upgrade |
EPS (Basic) | - | -151.31 | -353.14 | -34.25 | 54.42 | 3.18 | Upgrade |
EPS (Diluted) | - | -151.31 | -353.14 | -37.03 | 54.42 | 3.18 | Upgrade |
EPS Growth | - | - | - | - | 1613.68% | - | Upgrade |
Free Cash Flow | -274,357 | -18,106 | -1,113,887 | -499,985 | -874,686 | 474,489 | Upgrade |
Free Cash Flow Per Share | - | -3.25 | -200.27 | -89.91 | -157.49 | 85.43 | Upgrade |
Dividend Per Share | - | - | - | - | - | 1.270 | Upgrade |
Gross Margin | 26.69% | 26.49% | 25.18% | 38.07% | 31.47% | 33.28% | Upgrade |
Operating Margin | -7.91% | -7.78% | -17.34% | 5.48% | 7.43% | 6.64% | Upgrade |
Profit Margin | -8.79% | -8.47% | -19.90% | -2.06% | 2.35% | 0.18% | Upgrade |
Free Cash Flow Margin | -2.87% | -0.18% | -11.28% | -5.42% | -6.80% | 4.74% | Upgrade |
EBITDA | -407,488 | -408,632 | -1,182,970 | 867,821 | 1,300,090 | 827,342 | Upgrade |
EBITDA Margin | -4.26% | -4.11% | -11.98% | 9.40% | 10.11% | 8.27% | Upgrade |
D&A For EBITDA | 349,928 | 364,932 | 529,299 | 361,987 | 344,132 | 163,346 | Upgrade |
EBIT | -757,415 | -773,563 | -1,712,269 | 505,834 | 955,958 | 663,997 | Upgrade |
EBIT Margin | -7.91% | -7.78% | -17.34% | 5.48% | 7.43% | 6.64% | Upgrade |
Effective Tax Rate | - | - | - | - | 26.21% | 72.16% | Upgrade |
Advertising Expenses | - | 520,032 | 563,934 | 403,189 | 343,127 | 413,150 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.